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HLA expression levels have been suggested to be genetically controlled by single
nucleotide polymorphisms (SNP) in the untranslated regions (UTR), and expression
variants have been associated with the outcome of chronic viral infection and
hematopoietic stem cell transplantation (HSCT). In particular, the 3′UTR rs9277534-G/A
SNP in HLA-DPB1 has been associated with graft-versus-host-disease after HSCT
(Expression model); however its relevance in different immune cells and its mode of
action have not been systematically addressed. In addition, there is a strong though
not complete overlap between the rs9277534-G/A SNP and structural HLA-DPB1T
cell epitope (TCE) groups which have also been associated with HSCT outcome (TCE
Structural model). Here we confirm and extend previous findings of significantly higher
HLA-DPB1 expression in B cell lines, unstimulated primary B cells, and monocytes
homozygous for rs9277534-G compared to those homozygous for rs9277534-A.
However, these differences were abrogated by interferon-γ stimulation or differentiation
into dendritic cells. We identify at least seven 3′UTR rs9277534-G/A haplotypes differing
by a total of 37 SNP, also characterized by linkage to length variants of a short tandem
repeat (STR) in intron 2 and TCE group assignment. 3′UTR mapping did not show any
significant differences in post-transcriptional regulation assessed by luciferase assays
between two representative rs9277534-G/A haplotypes for any of eight overlapping
fragments. Moreover, no evidence for alternative splicing associated with the intron 2
STR was obtained by RT-PCR. In an exemplary cohort of 379 HLA-DPB1 mismatched
donor-recipient pairs, risk prediction by the Expression model and the Structural TCE
model was 36.7% concordant, with the majority of discordances due to non-applicability
of the Expression model. HLA-DPB1 from different TCE groups expressed in the absence
of the 3′UTR at similar levels by transfected HeLa cells elicited significantly different
mean alloreactive CD4+ T-cell responses, as assessed by CD137 upregulation assays
in 178 independent cultures. Taken together, our data provide new insights into the cell
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type-specific and mechanistic basis of the association between the rs9277534-G/A SNP
and HLA-DPB1 expression, and show that, despite partial overlap between both models
in HSCT risk-prediction, differential alloreactivity determined by the TCE structural model
occurs independently from HLA-DPB1 differential expression.
Keywords: HLA-DPB1, expression levels, SNP, rs9277534, hematopoietic stem cell transplantation, high risk
non-permissive mismatches, T cell epitope, T cell alloreactivity
INTRODUCTION
Genetic control of HLA expression is a topic of increasing
interest due to accumulating evidence for its relevance in
different biomedical areas including infectious disease and
transplantation. In particular, expression levels of HLA-A, -
C and -DPB1 genes have been shown to be associated with
specific single nucleotide polymorphism (SNP) variation in
the untranslated regions (UTR) (1–5). The presence of high-
expression variants was in turn associated with poor clearance
of chronic viral infections including HIV (1, 6) and HBV (5),
suggesting mechanistically increased natural killer (NK) cell
inhibition and higher T cell tolerance, respectively. Interest in
HLA expression was further fostered by the observation that
donor-recipient HLA mismatches involving a high-expression
variant in the patient are associated with the risks of developing
graft-versus-host-disease (GvHD) after Hematopoietic Stem Cell
Transplantation (HSCT), both for HLA-C (7) and HLA-DPB1
(8). The latter involves the bi-allelic SNP rs9277534, with the
G-variant leading to high expression and the A-variant to low
expression.
The mechanisms underlying the above-mentioned
associations between SNP variation and HLA expression
are only partly elucidated. For HLA-A, they have been suggested
to be correlated with differential methylation and/or the usage
of different polyadenylation sites (PAS) (2, 3). For HLA-C
and HLA-DPB1, no specific mechanisms for the observed
genetic control of expression levels have been postulated to
date. Moreover, the association of the rs9277534-G/A SNP with
HLA-DPB1 expression has been demonstrated only in a limited
set of immune cells of the B cell lineage (5, 8).
Two conceptually different models of HLA-DPB1 mismatches
associated with favorable or less favorable outcome of unrelated
HSCT have been developed in recent years, and have been
validated in independent clinical studies (8–14). The Expression
model is based on the assumption that patient-specific HLA-
DP antigens with high levels of cell surface expression could
be recognized more efficiently by alloreactive donor T cells
than patient-specific HLA-DP antigens with low levels of cell
surface expression. Therefore, genetic association of HLA-DPB1
expression with the bi-allelic rs9277534 SNP in the 3′UTR is
used to assign high or low expression levels to alleles carrying
the G- or the A-variant, respectively (5). The TCE Structural
model considers variability in the HLA-DPB1 coding sequence
translating into polymorphisms in the peptide binding domain,
which in turn leads to the generation of structural epitopes
recognized by alloreactive T cells. Based on this, at least three
different TCE groups were identified, each comprising different
HLA-DPB1 alleles sharing the relevant structural epitope. TCE
group assignment of HLA-DPB1 alleles was defined either by
cross-reactivity of alloreactive T cells (9) or, more recently, by the
combined median impact of polymorphic amino acids on T-cell
alloreactivity, termed functional distance (FD) (15). The three
TCE groups are not equivalent but follow a hierarchical order
of immunogenicity, with TCE group 1 > TCE group 2 > TCE
group 3. Interestingly, due to strong linkage disequilibrium (LD)
between the HLA-DPB1 3′UTR and its coding sequence, there
is a strong though not complete overlap between HLA-DPB1
alleles carrying the rs9277534 SNP and the structural TCE groups
(16). The relationship between the rs9277534 SNP Expression
model and the TCE structural mismatch model for high-risk
non-permissive HLA-DPB1 mismatches in HSCT is currently
unknown.
In this study, we have set out to fill these gaps by (i)
investigating rs9277534 SNP association with transcriptional
and cell surface HLA-DPB1 expression in different Antigen
Presenting Cells (APC); (ii) 3′UTR haplotype mapping of
different HLA-DPB1 alleles and functional testing of their
regulatory activity; (iii) comparing the demographics of risk
prediction based on the Expression model and the TCE
Structural mismatch model for HLA-DPB1 in an exemplary
cohort of unrelated HSCT; and (iv) assessment of in vitro T cell
alloreactivity against different HLA-DPB1 TCE groups at similar
transcriptional expression levels in transfected APC.
MATERIALS AND METHODS
Cells and Cell Lines
Peripheral blood mononuclear cells (PBMC) were obtained from
healthy blood donors from the University Hospital Essen after
informed consent under Ethical Review Board approval, in
accordance with the Declaration of Helsinki. EBV-transformed
B lymphoblastoid cell lines (BLCL) were generated from
PBMC by standard procedures (17), or purchased from the
European Collection of Authenticated Cell Cultures (ECACC).
HLA-DPB1 typing of the healthy donors was performed
by sequence-specific oligonucleotide probing (LABType SSO,
One Lambda, Canoga Park, CA, USA) according to the
manufacturer’s recommendations, under accreditation by the
European Federation for Immunogenetics. A list of PBMC
and BLCL used in this study and their HLA-DPB1 types is
presented in Tables 1, 2. Typing of the rs9277534 SNP was
performed by sequence-specific primer (SSP) PCR (Table 3),
and confirmed by Sanger sequencing of the 3′UTR following
published methods (5).
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TABLE 1 | BLCL used in this study.
BLCLa HLA-DPB1* Application
in this studyd
Allele rs9277534b 3′UTR
Haplotypec
MGAR 04:01 AA 6 Exp, Hap, Luc
MOU 02:01 AA 6 Exp, Hap, Luc
SWEIG007 04:02 AA 6 Exp, Hap
OSR-6924 02:01, 04:02 AA 6 Exp, Luc
OSR-2674 04:01, 17:01 AA 6 Exp
OSR-7891 04:01, 17:01 AA 6 Exp
OSR-5678 02:02, 04:01 AA 6 Exp
OSR-1629 02:01 AA 6 Exp
OSR-2674 04:01, 17:01 AA 6 Exp
BM21 10:01 GG 1 Exp, Hap, Luc
APA 05:01 GG 1 Exp, Hap, Luc
BEL7MON 03:01 GG 1 Exp, Luc
AKIBA 09:01 GG 1 Exp, Hap
KAS116 13:01 GG 3 Exp, Hap
PLH 15:01 GG 1 Exp, Hap
SLE005 03:01 GG 1 Exp, Hap
VAVY 01:01 GG 2 Exp, Hap
H0301 05:01 GG 1 Exp
aBLCL were purchased from the ECACC (regular font), or generated locally (italic).
brs9277534-G/A as determined locally.
c3′UTR haplotypes refer to those identified in Table 5.
dUse in this study for quantification of HLA-DPB1 protein and transcript expression (Exp),
3′UTR haplotype sequencing (Hap), or Luciferase assays (Luc).
Stable single HLA-DP HeLa cells transfectants (HeLa-II)
were generated by retroviral gene transfer of HLA-DPB1 and
DPA1 together with the invariant chain (Ii), HLA-DM, and
CD80 as previously described (18). Monocyte-derived dendritic
cells (DC) were obtained from frozen PBMC after MicroBead
sorting of CD14+ cells (Miltenyi Biotec, Bergisch Gladbach,
Germany) and incubation with 500 IU/mL Interleukin (IL)-
4 (R&D systems, Minneapolis, MN, USA) and 1000 IU/mL
Granulocyte Macrophage Colony-Stimulating Factors (GM-CSF;
Miltenyi Biotec, Bergisch Gladbach, Germany) for 5 days.
Immature and mature DC were subsequently obtained by
incubation with medium alone or in the presence of 10 ng/mL
IL-1β (Miltenyi Biotec, Bergisch Gladbach, Germany), 10 ng/mL
tumor necrosis factor (TNF)-α (Miltenyi Biotec, Bergisch
Gladbach, Germany), 1000 IU/mL IL-6 (Miltenyi Biotec,
Bergisch Gladbach, Germany), and 1µg/mL prostaglandin
E2 (PGE2) (Sigma Aldrich, St.Louis, MO, USA) for 24 h,
respectively, as described (19). Immature and mature DC were
discriminated by the presence or absence of CD83 within the
DC population identified as positive for CD11c and negative for
CD14 (20).
Monoclonal Antibodies (mAb) and Flow
Cytometry
The following mAb were used: CD3 krome orange [clone
UCHT1] (Beckmann Coulter, Brea, CA, USA), CD4
phycoerythrin-cyanin 7 (PE-Cy7) [clone SK3] (BD Bioscience,
Franklin Lakes, NJ, USA), CD8 pacific blue [clone B9.11]
(Beckmann Coulter), CD11c PE [clone S-HCL3] (BD
Bioscience), CD14 fluorescein isothiocyanate (FITC) [clone
MφP9] (BD Bioscience), CD19 allophycocyanin [clone HIB19]
(BD Bioscience), CD137 allophycocyanin [clone 4B4-1] (BD
Bioscience), CD83 PE [clone HB15] (Miltenyi Biotec), HLA-DP
PE [clone B7/21] (21) (Leinco Technologies, Inc. St.Louis, MO,
USA), HLA-DR PE [clone L243] (BD Bioscience), murine IgG2A
PE [clone S43.10] (Miltenyi Biotec) and murine IgG3 PE [clone
A112-3] (BD Bioscience). Flow cytometric determinations were
performed on a GalliosTM 10/3 cytometer (Beckman Coulter,
Brea, CA, USA), using the Kaluza for Gallios Acquisition
software (Version 1.0, Beckman Coulter) and the data were
analyzed with Kaluza Analysis Software (Version 1.3, Beckman
Coulter).
Quantification of HLA-DP and DR Cell
Surface Expression Levels
HLA-DP and HLA-DR cell surface expression levels were
quantified by flow cytometry staining by converting the median
fluorescence intensity (MFI) observed with the relevantmAb into
Molecules of Equivalent Soluble PE (MEPE) (22), using Sphero
Rainbow Calibration Particles (Spherotech, Lake Forest, IL,
USA) according to the manufacturer’s recommendations. MEPE
values were corrected for non-specific binding by subtracting
the corresponding fluorescent background detected with isotype
controls. Gating strategies were as follows: BLCL were analyzed
as homogenous population in forward and side scatter dot plots;
primary B cells and monocytes were gated in total PBMC as
negative for CD4 and CD8 but positive for CD19 or CD14,
respectively, before or after 48 h incubation with 200 IU/ml IFN-
γ (Axxora, Farmingdale, NY, USA); immature and mature DC
were analyzed by gating cells negative for CD14 and positive for
CD11c after in-vitro differentiation.
Quantification of HLA-DPB1 Transcript
Levels
HLA-DPB1 transcript levels were quantified from reverse
transcribed cDNA by quantitative PCR (qPCR). Total RNA
was extracted from 0.5–5 × 106 cells using the PureLink RNA
mini kit (ThermoFisher Scientific, Waltham, MA, USA), and
cDNA was synthetized from 0.5 to 2 µg total RNA with the
High Capacity cDNA Reverse Transcription Kit (ThermoFisher
Scientific). qPCR reactions were designed based on SYBR Green
chemistry (ThermoFisher Scientific) using a previously described
qPCR for GAPDH (5) as normalizer. The normalized amount
of HLA-DPB1 mRNA was expressed as 2−deltaCt with delta
Ct = CtHLA-DPB1 −CtGAPDH. qPCR primers, conditions and
characteristics are shown in Table 3.
Identification of HLA-DPB1 3′UTR
Haplotypes
HLA-DPB1 3′UTR nucleotide sequences were aligned from the
IMGT/HLA database release 3.31.0 (2018-01) (23). Haplotypes
were assigned according to polymorphisms located in the first
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TABLE 2 | PBMC used in this study.
HLA-DPB1* Application in this studyd
PBMCa Allelea rs9277534b 3′UTR
Haplotypec
UKE-9117 04:01, 04:02 AA 6 Exp(B,Mono,DC), T-cell culture
UKE-9149-04 02:01, 04:01 AA 6 Exp(B,Mono,DC), T-cell culture
UKE-9169-02 02:01, 04:01 AA 6 Exp(B,Mono,DC), T-cell culture
UKE-9169-03 04:01, 04:02 AA 6 Exp(B,Mono,DC), T-cell culture
UKE-9731 02:01, 04:01 AA 6 Exp(B,Mono,DC), T-cell culture
UKE-11103 02:01, 04:01 AA 6 Exp(B,Mono,DC), T-cell culture
UKE-11154 02:01, 04:01 AA 6 Exp(B,Mono,DC), T-cell culture
UKE-9068 02:01, 04:02 AA 6 Exp(B,Mono,DC)
UKE-9765 04:01, 04:02 AA 6 Exp(B,Mono,DC)
UKE-11116 02:01, 04:01 AA 6 Exp(B,Mono,DC)
UKE-9133-01 01:01, 13:01 GG 2, 3 Exp(B,Mono,DC)
UKE-9157 01:01, 03:01 GG 1, 2 Exp(B,Mono,DC)
UKE-8305B 01:01, 11:01 GG 2, 3 Exp(B,Mono,DC)
UKE-8097-A 01:01, 03:01 GG 1, 2 Exp(B,Mono,DC)
UKE-020215B 01:01, 03:01 GG 1, 2 Exp(B,Mono,DC)
UKE-8461C 01:01, 03:01 GG 1, 2 Exp(B,Mono,DC)
UKE-11012B 03:01, 13:01 GG 1, 3 Exp(B,Mono,DC)
UKE-11055A 01:01, 13:01 GG 2, 3 Exp(B,Mono,DC)
UKE-11209A 01:01, 03:01 GG 1, 2 Exp(B,Mono,DC)
UKE-11209B 03:01 GG 1 Exp(B,Mono,DC)
UKE-11177 02:01, 04:01 AA 6 Exp(B,Mono)
UKE-7547 03:01 GG 1 Exp(B,Mono)
UKE-8117A 04:01, 04:02 AA 6 T-cell culture
UKE-7595 04:01 AA 6 T-cell culture
UKE-7903-3 04:01, 04:02 AA 6 T-cell culture
UKE-020215A 04:01 AA 6 T-cell culture
UKE-8522C 04:01 AA 6 T-cell culture
UKE-7903-2 02:01, 04:02 AA 6 T-cell culture
UKE-8251C 02:01, 04:01 AA 6 T-cell culture
UKE-8360A 02:01, 04:01 AA 6 T-cell culture
UKE-8522A 02:01, 04:02 AA 6 T-cell culture
UKE-8522B 02:01, 04:02 AA 6 T-cell culture
UKE-10999 04:01 AA 6 T-cell culture
UKE-11012A 04:01, 04:02 AA 6 T-cell culture
UKE-10917 04:01, 04:02 AA 6 T-cell culture
UKE-9595 04:01, 04:02 AA 6 T-cell culture
UKE-9822 04:01 AA 6 T-cell culture
UKE-9110 02:01, 04:01 AA 6 T-cell culture
UKE-7964-2 04:01 AA 6 T-cell culture
UKE-9320B 02:01, 04:01 AA 6 T-cell culture
UKE-10294A 04:01 AA 6 T-cell culture
UKE-7713 03:01, 04:02 AG 1, 6 T-cell culture
UKE-7964-1 03:01, 04:02 AG 1, 6 T-cell culture
UKE-120315 03:01, 04:02 AG 1, 6 T-cell culture
UKE-8360B 03:01, 04:02 AG 1, 6 T-cell culture
UKE-9487 03:01, 04:01 AG 1, 6 T-cell culture
UKE-9751C 03:01, 04:02 AG 1, 6 T-cell culture
UKE-8097B 02:01, 03:01 AG 1, 6 T-cell culture
UKE-8461A 02:01, 03:01 AG 1, 6 T-cell culture
UKE-8360C 04:01, 14:01 AG 1, 6 T-cell culture
UKE-9145 04:01, 14:01 AG 1, 6 T-cell culture
aPBMC were isolated from peripheral blood of 51 healthy individuals. HLA-DPB1* allele typing was performed as described in Materials and Methods.
brs9277534-G/A typing was determined by SSP-PCR as described in Materials and Methods.
c3′UTR haplotypes were assigned based on the linkage disequilibrium to HLA-DPB1 alleles as reported in Table 4.
dPBMC samples were used for quantification of HLA-DPB1 expression (Exp) in B cells (B), monocytes (Mono) and dendritic cells (DC), and/or in functional testing of alloreactive T-cell
cultures stimulated with HeLa cells expressing single HLA-DPB1 antigens (T-cell culture).
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TABLE 3 | PCR reactions used in this study.
Reactiona Typeb Purpose Primersc Cycling
conditions
Efficiencyd
rs9277534
SSP-PCR
STD-PCR rs9277534 SNP
typing
FW-A:‘ATCCATTTATGTCTCAGACCA’
(rs9277534-A)
FW-G:‘TCCATTTATGTCTCAGACCG’
(rs9277534-G)
RV: ‘GGTCCTATCAGGCAGATTTGCAG’
(both)
95◦C for 15”
60◦C for 30”
72◦C for 30”
N.A.
HLA-DPB1 short
mRNA
qPCR Gene expression FW-a:‘AAGAAAGTTCAACGAGGATCTGC’
(exon 5)
RV-b:‘GAAGAAGGGAACATGGTTGGAG’
(exon 6)
95◦C for 15”
62◦C for 1’
92%
HLA-DPB1 long
mRNA
qPCR Gene expression FW-c:‘ATGACACTCTTCTGAATTGACTG’
(exon 6)
RV-d:‘GGTAATGATAAAACATGCTCTC‘
(exon 6)
95◦C for 15”
62◦C for 1’
97%
F1e STD-PCR Molecular
cloning
FW-F1A:‘ACAGGGTTCCTGAGCTC’
(A-haplotype)
RV-F1A:‘TTGGAAGTTGAAGGTCTGTC’
(A-haplotype)
FW-F1G:‘ACAGGGTTCCTGACCTC’
(G-haplotype)
RV-F1G:‘TGGGAAGCTGAGGGTC’
(G-haplotype)
95◦C for 15”
63◦C for 30”
72◦C for 30”
N.A.
F2e STD-PCR Molecular
cloning
FW-F2A:‘TCCAGGACAGACCTTCAAC’
(A-haplotype)
FW-F2G:‘TCCAGGACAGACCCTCAG‘
(G-haplotype)
RV-F2:‘GAAACAGTGCTTTGAATCAAAGAGC’
(both)
F3e STD-PCR Molecular
cloning
FW-F3:‘GCTCTTTGATTCAAAGCACTG’
(both)
RV-F3A: ‘AAACAAACAGTCATGTTGGG‘
(A-haplotype)
RV-F3G:‘AAACAAACACTTATGTTGGGTTTTG’
(G-haplotype)
F4e STD-PCR Molecular
cloning
FW-F4A:‘CAAAACCCAACATGACTGTTTG’
(A-haplotype)
RV-F4A:’TTATTAACTCCTACTGTCTACTAAAACC‘
(A-haplotype)
FW-F4G:’CAAAACCCAACATAAGTGTTTG’
(G-haplotype)
RV-F4G:’TTATTAACTCCTACTGTTTACTAAAACCC‘
(G-haplotype)
F5e STD-PCR Molecular
cloning
FW-
F5A:‘TTTAGTAGACAGTAGGAGTTAATAAAGAAG’
(A-haplotype)
RV-F5A:’CCATTATACAATAGTTAACATATCCCC‘
(A-haplotype)
FW-F5G:
’TTTAGTAAACAGTAGGAGTTAATAAAGAAG’
(G-haplotype)
RV-F5G:’ ACATTATACAATAGTTAACATATCTCCAC’
(G-haplotype)
F6e STD-PCR Molecular
cloning
FW-F6A:‘GGATATGTTAACTATTGTATAATGGGG’
(A-haplotype)
FW-F6G:’AGATATGTTAACTATTGTATAATGTGGC’
(G-haplotype)
RV-F6:‘GAGGGCACTAAACTTGATTTG’
(both)
95◦C for 15”
63◦C for 30”
72◦C for 30”
N.A.
(Continued)
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TABLE 3 | Continued
Reactiona Typeb Purpose Primersc Cycling
conditions
Efficiencyd
F7e STD-PCR Molecular
cloning
FW-F7:‘CCCCCAAATCAAGTTTAGTG’
(both)
RV-F7A:‘TGGGTCCTATCAGGCAG’
(A-haplotype)
RV-F7G:‘CGGGTCCTATCAGGC’
(G-haplotype)
F8e STD-PCR Molecular
cloning
FW-F8:‘CTGCAAATCTGCCTGATAG’
(both)
RV-F8: ‘TTCATTTAACTTCTTAATGGTAATGATAAAAC’
(both)
HLA-DPB1 exon
2-4 splicing
RT-PCR Alternative
splicing
FW-e:‘GCTTCCTGGAGAGATACATC’
(exon 2)
RV-f:‘CAGCTCGTAGTTGTGTCTGC’
(exon 2)
RV-g:‘TTGAATGCTGCCTGGGTAG’
(exon 3)
RV-h: ‘AGCTCCCGTCAATGTCTTAC’
(exon 4)
95◦C for 1’ 55◦C
for 30” 72◦C for 1’
N.A.
HLA-DPB1
exon 2
qPCR Gene expression FW-e:‘GCTTCCTGGAGAGATACATC’
(exon 2)
RV-f:’CAGCTCGTAGTTGTGTCTGC’
(exon 2)
95◦C for 15” 62◦C
for 1’
100%
aReactions are reported in order of appearance.
bSTD-PCR: standard PCR performed on genomic or plasmid DNA. qPCR: quantitative real-time PCR performed on cDNA obtained as described in Materials and Methods. RT-PCR:
reverse transcriptase PCR performed on cDNA as described in Materials and Methods. STD-PCR and RT-PCR were performed using Amplitaq GOLD DNA polymerase and buffer
(ThermoFisher Scientific), qPCR were performed using SYBR Green Real-time Mastermix (ThermoFisher Scientific).
cFor each primer, name, sequence, and target region or polymorphism in HLA-DPB1 are reported. FW: forward primer; RV: reverse primer.
dEfficiency of qPCR reactions was calculated by quantifying the target template in 5-fold serial dilution of cDNA for 10 ng to 16 pg. All qPCR reactions resulted in high reaction efficiency
comparable to the qPCR targeting GAPDH as reference gene (Efficiency = 93%) (5).
eF1-F8 fragments of the HLA-DPB1 3′UTR from A- or G-Haplotype were amplified by PCR and subsequently cloned downstream of luciferase gene Luc2 in pmirGLO vector (see also
Figure 5). The following restriction sites were added at the 5’ of each primer: NheI for forward primers and SalI for reverse primers.
671 bp of the transcribed 3′UTR, i.e., the last 4 bp of exon 5 and
the first 667 bp of exon 6. The nucleotide sequence of selected
haplotypes was confirmed by direct Sanger sequencing (Seqlab,
Göttingen, Germany) on both strands of a 667 bp 3′UTR PCR
fragment obtained from genomic DNA according to previously
described protocols (5).
Dual Luciferase Assay
HLA-DPB1 3′UTR fragments or control wild-type (WT)
and mutant (mut) target sequence of hsa-miR-21 (mir21-
WT and mir21-mut) were pre-amplified by PCR (primers
and conditions in Table 3) or synthetized in vitro (Eurofins
Genomics, Ebersberg, Germany). 3′UTR fragments and controls
were cloned into the pmirGLO vector (Promega, Madison,
WI, USA) downstream of the luciferase reporter gene (luc2)
and transfected into HeLa cells or BLCL by electroporation
with the Neon transfection system (Invitrogen, USA), according
to the manufacturer’s recommendations. Luciferase activity
was measured after 24 h with a Dual Luciferase Reporter
Assay System (Promega) using the monochromator multimode
microplate reader LB 943 Mithras² (Berthold Technologies, Bad
Wildbad, Germany). Luciferase activity under the control of
mir21-WT or mir21-mut was used as positive and negative
controls, respectively, since the expression of the relevant miRNA
hsa-miR-21 was shown to be abundant in both HeLa and
BLCL (24, 25). The Renilla luciferase gene (hRluc-neo fusion)
included in the same vector was used as transfection control for
normalization of the luc2 signal.
Assessment of Splicing in HLA-DPB1
mRNA by RT-PCR
Splicing between exons 2–4 of HLA-DPB1 mRNA was
assessed by standard RT-PCR on total RNA extracted
from BLCL; RNA and reverse-transcribed cDNA were
prepared as described above. cDNA samples were used
as template for 3 PCR reactions designed to target exon
2 alone, exon 2–3, and exon 2–4 with primers and
PCR condition described in Table 3. Analysis of the
PCR products was performed using standard agarose gel
electrophoresis.
Alloreactive T-Cell Cultures
Alloreactive T-cell effectors were raised against individual HLA-
DP alloantigens by in vitro stimulation of CD4+ T cells with
HeLa-II cells. Briefly, CD4+ T cells were isolated from frozen
PBMC of HLA-DPB1-typed healthy blood donors (Table 2)
by MicroBeads sorting (Miltenyi Biotec, Bergisch Gladbach,
Germany), and stimulated for 14 d at a 3:1 ratio with irradiated
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(100Gy) HeLa-II expressing the allogeneic HLA-DPB1 allele
of interest in culture medium supplemented with 10% heat-
inactivated AB human serum (Sigma-Aldrich) and 50 IU/mL IL-
2 (Miltenyi Biotec, Bergisch Gladbach, Germany). After 2 weeks,
T cells were re-stimulated for 24 h with fresh HeLa-II carrying
the relevant allogeneic HLA-DPB1 allele or autologous HLA-
DPB1 allele(s), or medium alone. The specific T-cell response was
quantified by flow cytometry as the percentage of gated CD4+
T cells upregulating cell surface expression of CD137, corrected
for the background response to HeLa-II expressing autologous
HLA-DPB1.
Statistical Analysis
Statistical analysis was performed using the Prism 6 software
(GraphPad Software, La Jolla, CA, USA), using the two-tailed
unpaired t-test or the Wilcoxon matched-pairs signed rank Test.
RESULTS
High and Low Cell Surface Expression of
HLA-DP in Relation to rs9277534 SNP in
Different Cell Types
Association of the bi-allelic rs9277534-G/A SNP variants with
high and low HLA-DP expression levels, respectively, was
originally reported by Thomas et al. on the cell surface of primary
B cells (5) and more recently observed at the transcriptional
level in BLCL by Petersdorf and collaborators (8). Here we
quantified HLA-DP cell surface expression on BLCL by MEPE
flow cytometry, using the mAb B7/21 which recognizes a
monomorphic determinant on HLA-DP (21) and was used
and validated also in the previous study by Thomas et al.
(5) (Figure 1A). Compared with rs9277534-A/A (AA), BLCL
homozygous for rs9277534-G/G (GG) showed significantly
higher amounts of HLA-DP molecules, while no difference
was observed in HLA-DR expression (Figure 1A, Table 4). On
primary B cells, we confirmed the original finding of Thomas
et al. with expression levels of HLA-DP significantly higher
in primary unstimulated B cells from healthy blood donors
homozygous for GG in comparison to AA, while no difference
was observed in HLA-DR expression (Figure 1B, Table 4).
Interestingly, overnight incubation with IFN-γ to simulate
inflammatory conditions abrogated these differences (Figure 1C,
Table 4).
To address the question whether these observations also apply
to other APC potentially relevant in allogeneic HSCT, we carried
out similar analyses in primary monocytes and monocyte-
derived DC. Similar to primary B cells, significant differences
for HLA-DP but not HLA-DR expression were found in primary
monocytes between individuals homozygous for rs9277534-A/A
or rs9277534-G/G (Figure 2A, Table 4), but these differences
were also abrogated after overnight incubation with IFN-γ
(Figure 2B, Table 4). Importantly, no significant differences
for either HLA-DP or HLA-DR expression were observed
in association with rs9277534 for immature DC (Figure 2C,
Table 4) or mature DC (Figure 2D, Table 4).
Genetic Control of HLA-DPB1
Transcriptional Levels in BLCL and DC
The HLA-DPB1 3′UTR is over 3000 bp in length and contains
three sets of PAS, located at position 235–240, 667, and 3162,
respectively (GenBank ID: NM_002121.5). The rs9277534 SNP
is located at position 496 between the first and the second PAS
which mediate the synthesis of at least two mRNA isoforms
of different length, a short one using the more proximal
and a long one using the more distal PAS. The rs9277534
SNP is contained in the long but not in the short transcript
(Figure 3A). Transcriptional expression levels of HLA-DPB1
were comparatively determined for the short and the long
transcript by qPCR in BLCL, immature and mature DC.
Consistent with previous reports (5, 8) and with our findings
on HLA-DP protein expression levels, BLCL homozygous for
rs9277534-G/G carried significantly higher transcript levels of
the short mRNA isoform lacking the rs9277534 SNP, compared
with rs9277534-A/A (mean normalized expression relative to
GAPDH was 0.1666 ± 0.08686 vs. 0.0665 ± 0.01387, p < 0.01.
Transcription levels of the long mRNA isoform including the
rs9277534 SNP were at least 2-log lower compared with the
short, and not significantly different between the two groups of
BLCL (mean normalized expression relative to GAPDH 0,0013
± 0.00114 vs. 0.0007 ± 0.00017, p = 0.18; Figure 3B). This
observation suggests that the rs9277534 SNP probably does not
have a direct role in regulating mRNA transcript levels in BLCL,
but that rather other, linked polymorphisms could mediate this
function. Consistent with our findings on protein expression
levels, no significant differences in the transcript levels of either
the short or the long mRNA isoform were observed in immature
and mature DC from individuals homozygous for rs9277534-
G/G or rs9277534-A/A (Figures 3C,D).
HLA-DPB1 3′UTR Haplotypes
Polymorphic variation in HLA-DPB1 is characterized by tight
LD which encompasses the entire genomic region from intron
2 to the 3′UTR (26). We aligned HLA-DPB1 3′UTR sequences
from common alleles identified in Europe (27) deposited in the
IMGT/HLA database (23) and found a total of 37 SNP, which
gave rise to a total of 7 different haplotypes, 5 linked to rs9277534-
G and 2 linked to rs9277534-A (Figure 4A and Table 5). The
5 rs9277534-G linked haplotypes 1-5 differ only by 1-3/37 SNP,
while at least 28/37 SNP differences are found in the 2 rs9277534-
A linked haplotypes 6 and 7, which in turn are strikingly similar
to each other. Interestingly, the haplotypes are in tight LD with
a STR located in intron 2 at 44 bp upstream of exon 3, with G-
and A-haplotypes linked with a short and a long STR, respectively
(Table 5). Moreover, LD also encompasses the exon sequences,
with TCE groups 1 and 2 linked with the G-haplotype and TCE
group 3 linked with the A-haplotype, although a number of
exceptions do exist (Table 5).
Mapping of Regulatory Elements in the
3′UTR of HLA-DPB1 by Luciferase Assays
In order to determine whether the rs9277534 itself and/or
other linked SNP might be directly involved in differential
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FIGURE 1 | HLA-DP and HLA-DR cell surface expression in relation with rs9277534 SNP in B cells. Cell surface staining for HLA-DP and HLA-DR was
performed with the mAb B7/21 and L243, respectively, on (A) BLCL (N = 17) (B,C) CD19+ B cells in PBMC after 48 h incubation with medium (N = 22, B) or with
200 IU/ml IFN-γ (N = 22, C). Cells were homozygous for either rs9277534-A/A (AA) or rs9277534-G/G (GG) (Tables 1, 2). Shown are two representative FACS plots
(left panel) and the Molecules of Equivalent Soluble PE (MEPE) of all samples (right panels). Statistical comparisons were performed by the two-tailed unpaired t-test
(n.s. not significant; *p < 0.05; **p < 0.01). Mean ± SD are reported in Table 4.
regulation of transcript abundance, the HLA-DPB1 3′UTR
was mapped into a total of eight overlapping fragments
of 100 bp each, covering the polymorphisms in the region
from the stop codon to the second PAS at position 667,
including rs9277534 in fragment F7 (Figure 4B). Fragments F1-
F8 from haplotypes 1 and 6, prototypes of rs9277534-G and
rs9277534-A haplotypes, respectively (Figure 4A and Table 5),
were cloned downstream of a luciferase reporter gene and
tested by standard luciferase assays in 4 different BLCL, a cell
type in which the genetic control of HLA-DPB1 transcript
levels by the rs9277534 SNP was evident. Significant differences
in luciferase activity were observed between mir21-WT and
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TABLE 4 | HLA-DP and HLA-DR cell surface expression in different cell types.
HLA-DPc HLA-DRc
APCa rs9277534 (N)b mean±SD p mean±SD p
BLCL AA (8) 2.45 × 105 ± 1.27 ** 7.48 × 105 ± 2.06 n.s.
GG (9) 5.22 × 105 ± 1.85 8.62 × 105 ± 1.44
B cell AA (11) 0.32 × 105 ± 0.15 * 1.64 × 105 ± 0.69 n.s.
GG (11) 0.50 × 105 ± 0.25 1.40 × 105 ± 0.67
B cells + IFN-γd AA (11) 0.44 × 105 ± 0.21 n.s. 1.82 × 105 ± 0.72 n.s.
GG (11) 0.68 × 105 ± 0.40 1.64 × 105 ± 0.82
Monocytes AA (11) 0.17 × 10e ± 0.17 * 1.61 × 105 ± 1.35 n.s.
GG (11) 0.37 × 105 ± 0.26 1.83 × 105 ± 1.26
Monocytes + IFN-γe AA (11) 1.02 × 105 ± 0.37 n.s. 4.46 × 105 ± 1.02 n.s.
GG (11) 1.31 × 105 ± 0.58 3.81 × 105 ± 1.29
Immature DC AA (10) 1.23 × 105 ± 0.95 n.s. 3.73 × 105 ± 2.60 n.s.
GG (10) 2.71 × 105 ± 2.20 3.84 × 105 ± 2.78
Mature DC AA (10) 5.56 × 105 ± 2.71 n.s. 10.62 × 105 ± 2.71 n.s.
GG (10) 6.86 × 105 ± 5.26 8.36 × 105 ± 3.69
aHLA-DP and HLA-DR expression was quantified by flow cytometry on the cell surface of different cell types as described in Materials and Methods. Lists of the APC used in this study
are reported in Table 1,2.
brs9277534-G/A as determined locally.
cCell surface expression of HLA-DP and HLA-DR are reported as converted MEPE values as described in Materials and Methods.
d IFN-γ significantly upregulated HLA-DP and DR expression on total B cells: HLA-DP untreated 0.41x105 ± 0.22 vs. IFN-γ treated 0.56x105 ±0.34 (p<0.0001); HLA-DR untreated
1.51x105 ± 0.67 vs. IFN-γ treated 1.73x105 ±0.76 (p<0.001).
e IFN-γ significantly upregulated HLA-DP and DR expression on total monocytes: HLA-DP untreated 0.27x105 ± 0.24 vs. IFN-γ treated 1.17x105 ±0.50 (p<0.0001); HLA-DR untreated
1.72x105 ± 1.28 vs. IFN-γ treated 4.14x105 ±1.18 (p<0.0001). Statistical comparisons were performed by two-tailed unpaired t-test (n.s. not significant; *p < 0.05; **p < 0.01).
mir21-mut used as positive and negative controls, respectively
(Figure 4C). Compared with the positive control, none of
the eight fragments, including F7 encompassing rs9277534,
was able to markedly reduce luciferase activity. Moreover and
importantly, no significant differences were observed when
comparing luciferase activity under the control of the same
fragment cloned from haplotype 1 or from haplotype 6
(Figure 4C). Taken together, these results did not define any
major regulatory element in the 3′UTR of HLA-DPB1, suggesting
that polymorphism in other regions of the gene might be
involved.
Assessment of Alternative Splicing
Associated With the HLA-DPB1 Intron 2
STR
We next asked whether the long isoform of the intron
2 STR, in linkage with the low expression rs9277534-A
variant (Table 5) (28), could induce a splicing defect involving
exon 3, which is in relatively close vicinity to the 3′ end
of the STR. The resulting hypothetical alternatively spliced
transcript would join exon 2 and exon 4, resulting in a
complete loss of function (Figure 5A). To test this hypothesis,
we designed PCR primers in exon 2, 3 and 4, which
would give rise to PCR products of different sizes in the
presence or absence of alternative splicing. In a total of
6 BLCL homozygous for a rs9277534-G or a rs9277534-A
haplotype, no evidence for alternative splicing was observed
(Figure 5B).
Expression Model vs. TCE Structural
Model of Donor-Recipient HLA-DPB1
Mismatches in HSCT
Two currently proposed HLA-DPB1 mismatch models, i.e.,
the Expression model and the TCE Structural model (Figure
6A), take the classical concept of donor-recipient matching for
polymorphic HLA-DPB1 alleles further to matching for HLA-
DPB1 allele groups. For the Expression model, each of the
two HLA-DPB1 alleles in patient and donor is assigned to the
rs9277534-G or –A group, based on tight LD between this SNP
and the different alleles (8). The Expression model is considered
to be predictive only for single HLA-DPB1 mismatches in GvH
direction, i.e., recipient and donor are matched for the HLA-
DPB1 allele on one haplotype but mismatched for the other.
These single mismatches are classified as unfavorable (“high-
risk”) if there is a patient-specific HLA-DPB1 allele not shared
by the donor which belongs to the high expression rs9277534-
G group, and as favorable (“low risk”) if it belongs to the
low expression rs9277534-A group. All other combinations,
including those in which there is no patient-specific single
mismatched allele, or in which patient and donor aremismatched
for HLA-DPB1 alleles on both haplotypes, cannot be classified
as favorable or unfavorable by the Expression model (“not
applicable”; Figure 6B, left panel). For the TCE Structural model,
each of the two HLA-DPB1 alleles in patient and donor is
assigned to one of the three TCE groups, and mismatches are
considered to be unfavorable (“non-permissive”) if the TCE
group of the highest order in the hierarchy is not shared between
patient and donor, while all other mismatch combinations
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FIGURE 2 | HLA-DP and HLA-DR cell surface expression in relation with rs9277534 SNP in monocytes and DC. Cell surface staining for HLA-DP and HLA-DR was
performed with the mAb B7/21 and L243, respectively, on (A,B) CD14+ monocytes in PBMC after 48 h incubation with medium (N = 22) (A) or with 200 IU/ml IFN-γ
(N = 22) (B), and on (C) monocyte-derived immature DC (N = 20) or (D) mature DC (N = 20). Cells were homozygous for either rs9277534-A/A (AA) or
rs9277534-G/G (GG) (Table 2). Shown are two representative FACS plots (left panel) and the Molecules of Equivalent Soluble PE (MEPE) of all samples (right panels).
Statistical comparisons were performed by the two-tailed unpaired t-test (n.s. not significant; *p < 0.05). Mean ± SD are reported in Table 4.
Frontiers in Immunology | www.frontiersin.org 10 October 2018 | Volume 9 | Article 2236
Meurer et al. HLA-DPB1 Expression and Structure in HSCT
FIGURE 3 | HLA-DPB1 transcriptional expression in relation with rs9277534 SNP in BLCL and DC. (A) Schematic representation of the HLA-DPB1 genomic structure
and a short and long form of mRNA generated by two different polyadenylation sites (PAS) about 400 bp apart, as reported in the GenBank database (ID:
NM_002121.5). Note that the long but not the short mRNA includes the rs9277534 SNP. Primer locations for qPCR quantification of both transcripts are indicated as
arrows a-b or c-d (see also Table 3). Primers “a” and “b” anneal to both the short and the long mRNA, while primers “c” and “d” are specific for the long mRNA. (B–D)
Short (left panel) and long (right panel) HLA-DPB1 mRNA was quantified in BLCL (N = 17, B), immature DC (N = 20, C) and mature DC (N = 20, D), by qPCR relative
to GAPDH as described in Materials and Methods. Cells were homozygous for either rs9277534-A/A (AA) or rs9277534-G/G (GG) (Tables 1,2). Statistical
comparisons were performed by the two-tailed unpaired t-test (n.s. not significant; **p < 0.01).
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FIGURE 4 | HLA-DPB1 3′UTR haplotype identification, mapping and regulatory activity. (A) 671 bp of the 3′UTR (i.e., from the last 4 bp of exon 5 to the first 667 bp
of exon 6) of 30 HLA-DPB1 alleles reported as common in Europe (Table 5) (27) were aligned from the IMGT/HLA database (23). Nucleotide polymorphism was
restricted to 37 bi-allelic SNP and one insertion/deletion (ins/del), and is listed with the respective position relative to the stop codon in exon 5. The rs9277534-G/A
SNP located at position 496 is indicated in bold. A total of 7 haplotypes were identified, 5 linked to rs9277534-G and 2 linked to rs9277534-A. Nucleotide
polymorphism is indicated with reference to the rs9277534-G linked haplotype 1, dashes indicate sequence identity. Haplotypes 1 and 6 were chosen for further
studies and are highlighted in gray. (B) Mapping of the HLA-DPB1 3′UTR. Eight overlapping fragments F1-F8, each 100 bp in length with an overlap of 25 bp, were
PCR-amplified from haplotype 1 (BLCL AKIBA, HLA-DPB1*09:01) or haplotype 6 (BLCL MOU, HLA-DPB1*04:01) and cloned into the pmirGLO dual luciferase vector
as described in Materials and Methods. Note that fragment F7 comprises rs9277534. (C) Gene regulation by HLA-DPB1 3′UTR fragments assessed with the dual
luciferase assay. Four different BLCL (APA, MOU, BM21, OSR-6924) were transfected with pmirGLO containing F1-F8 from haplotype 1 (rs9277534-G linked, gray
bars) or from haplotype 6 (rs9277534-A linked, black bars), respectively, and tested in 3 independent experiments by dual luciferase assays as described in Materials
and Methods. A total of 12 independent analyses were performed for each fragment. 50 bp fragments containing the miR21 WT or mutated target sequence were
used as positive and negative control, respectively (striped bars). Results are expressed as mean of fold-change of luciferase activity respect to renilla (luc/ren). Bars
refer to SD between 12 independent experiments. Statistical comparisons were performed by the Wilcoxon matched-pairs signed rank Test (**p < 0.001).
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TABLE 5 | HLA-DPB1 3′UTR haplotypes identified in this study.
HLA-DPB1*
3′UTR
Haplotype
Frequencya Alleleb TCE
groupc
Expression
SNPd
Intron 2
STRe
1 0.191 03:01f 2 G (GGAA)4
05:01 3
06:01 2
09:01f 1
10:01f 1
14:01 2
15:01f 3
45:01 2
63:01 3
130:01 3
2 0.062 01:01f 3
26:01 3
3 0.045 11:01 3
13:01f 3
4 0.006 19:01 2
34:01 3
5 n.o. 18:01 3
6 0.677 02:01f 3 A (GGAA)10−16
02:02 3
04:01f 3
04:02f 3
17:01 1
23:01 3
41:01 3
46:01 3
47:01 3
105:01 3
124:01 2
126:01 3
7 n.o. 30:01 1
aCombined frequency of HLA-DPB1 alleles as reported in www.allelefrequencies.net
database (England Northwest population, N=2960), n.o. not observed.
bListed are only those HLA-DPB1 alleles reported to be common in Europe (27).
cTCE group assigned according to Crivello et al (15).
dLinked allelic variant at SNP rs9277534 associated with high (G) or low (A) HLA-DPB1
expression (8).
eNumber of repeated units of the STR (AAGG)n in Intron 2 of HLA-DPB1 as reported in
IMGT/HLA databank (Release 3.31.0 2018-01, http://www.ebi.ac.uk/ipd/imgt/hla).
fFor this allele, the 3′UTR sequence was confirmed by direct sequencing on a
homozygous BLCL as listed in Table 2.
are considered to be favorable (“permissive”; Figure 6B, right
panel).
Risk prediction by the Expression model and the TCE
Structural model was comparatively evaluated in 379 HLA-
DPB1-mismatched donor-recipient pairs from the University
Hospital Essen (29). In the Expression model, 73 (19.3%) and 130
(34.3%) were classified as high or low-risk, respectively, while 176
(46.4%) pairs were “not applicable” because they did not satisfy
the pre-requisite of single HLA-DPB1 allele mismatches in GvH
direction (Figure 6C, upper left panel). In the TCE Structural
model, all 379 (100%) pairs could be classified and of these,
175 (46.2%) and 204 (53.8%) fell into the non-permissive or the
permissive group, respectively (Figure 6C, upper right panel).
The overall concordance between the two models was 36.7%
with assignment as permissive/low risk in 98/379 (25.9%) and
non-permissive/high risk in 41/379 (10.8%) pairs, respectively.
240/379 (63.3%) assignments were discordant. These were
due to differential risk prediction in 64/379 (16.8%) pairs,
with even distribution between permissive/high risk and non-
permissive/low risk, each occurring in 32/379 (8.4%) pairs
(Figure 6C, lower panel). The remaining discordances were
due to non-applicability of the expression model, occurring
in 176/379 (46.5%) pairs. Of these, a slightly higher number
(102/176; 58%) was classified as non-permissive, compared
to the remaining 74/176 (42%) pairs classified as permissive,
corresponding to an overall percentage of 26.9% and 19.6%,
respectively, in the cohort overall (Figure 6C, lower panel).
T-Cell Alloreactivity To HLA-DP Expressed
in HeLa-II Cells in the Absence of the
3′UTR
The most frequent HLA-DPB1 alleles in rs9277534-G and
rs9277534-A haplotypes belong to TCE groups 1/2 and TCE
group 3, respectively (Table 5). However, a few exceptions
exist, in particular HLA-DPB1∗17:01 from TCE group 1, which
is associated with the rs9277534-A haplotype 6, and HLA-
DPB1∗01:01 and ∗05:01, both of which are found in linkage with
the rs9277534-G haplotypes 2 and 1, respectively (Table 5 and
Figure 7A). We expressed 5 HLA-DPB1 alleles representative
of the “correct” association (HLA-DPB1∗09:01, ∗10:01 – TCE
group 1 and rs9277534-G; HLA-DPB1∗02:01, ∗04:01, ∗04:02 –
TCE group 3 and rs9277534-A), as well as the 3 abovementioned
alleles with the “inverted” association in HeLa-II cells, under the
control of a retroviral promoter (18), in the absence of the 3′UTR
(Figure 7A). As expected, the significant differences observed in
BLCL between transcript levels of HLA-DPB1 alleles from TCE
group 1 (rs9277534-G) and TCE group 3 (rs9277534-A) were
abrogated in transduced HeLa-II cells (Figure 7B).
The transduced HeLa-II cells were used in a total of 178
independent cultures for a 14-day stimulation of CD4+ T cells
from healthy donors expressing at least one HLA-DPB1 allele
from TCE group 3 and a second allele from either TCE group
2 or 3, for whom allogeneic HLA-DPB1 alleles from TCE
group 1 and TCE group 3 represent a non-permissive and a
permissive mismatch, respectively. The alloreactive response was
measured after overnight re-challenging with the original target
cell, compared to HeLa-II transduced with autologous HLA-
DPB1 as background control, as the percentage of CD4+ T
cells up-regulating the activation marker CD137, which has been
shown to best describe the total pool of alloreactive T cells (30)
(Figure 8A). In line with our previous reports (31), the mean
alloresponse to HeLa-II transfected with HLA-DPB1 alleles from
TCE group 1 (non-permissive mismatch) was significantly higher
compared with TCE group 3 (permissive mismatch; 36.43±12.13
vs. 19.00 ± 15.58, p < 0.0001, Figure 8B). Consistent with its
classification as TCE group 1, the median response to allogeneic
HLA-DPB1∗17:01 was also significantly higher compared with
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FIGURE 5 | HLA-DPB1 exon 2–4 splicing in HLA-DPB1 rs9277534-G/A haplotypes. (A) A short tandem repeat (STR) of 4 or 10-16 GGAA repeats associated with
the rs9277534-G or -A SNP, respectively, is located 44 bp upstream of exon 3 (Table 5) (28). The longer STR variant might facilitate splicing of exon 3, giving rise to
an alternative splice product joining exons 2 and 4, which would not produce a functional HLA-DP protein. To test this hypothesis, PCR amplicons were generated
using a common forward primer “e” in exon 2, and 3 reverse primers “f”, “g” and “h” in exon 2, 3 and 4, respectively. (B) RT-PCR on RNA from 6 BLCL carrying the
rs9277534-G or -A linked haplotypes 1 and 6, respectively (Table 4). Shown is agarose gel electrophoresis obtained with primer pairs e-f, e-g and e-h on one
representative BLCL for each haplotype (A or G). All three PCR products of 182 bp, 311 bp and 492 bp respectively were produced, while the 254 bp expected for
alternative splicing was absent in both haplotypes. M; Molecular weight marker; Ctrl; no template control.
TCE group 3 (38.58 ± 13.96, p < 0.0001, Figure 8B), and
not significantly different from TCE group 1, despite similar
cell surface expression levels (Figure 7B). For HLA-DPB1∗01:01,
responses were highly variable (27.68 ± 19.26) and significantly
different from other alleles of both TCE group 1 and TCE group
3 although both with a low level of significance (p < 0.05
each). Similar levels of responses were also seen against HLA-
DPB1∗05:01 (30.75 ± 14.85), although these were significantly
different (p < 0.01) from TCE group 3 but not from TCE
group 1 (Figure 8B). These data suggest that HLA-DPB1∗01:01
and 05:01 appear to represent a functionally distinct TCE
group. Taken together, our data demonstrate that also in the
absence of significant differences of transcriptional HLA-DPB1
alleles on HeLa-II cells, differential in vitro T-cell alloreactivity
against permissive and non-permissive mismatches can be
appreciated.
DISCUSSION
Our study provides new insights into the cell type-specific and
mechanistic basis of the association between the rs9277534 SNP
andHLA-DPB1 expression, and into the relationship between the
Expression model and the TCE Structural model for HLA-DPB1
mismatch risk prediction in HSCT.
We are the first to broaden observations on the genetic control
of HLA-DPB1 expression from BLCL and primary unstimulated
B cells, in which this issue has been studied so far (5, 8), to other
cell types likely to play a role in GvHD, such as DC and IFN-γ-
stimulated B cells and monocytes. We confirm the previous data
from the literature, but also show that the observed differences
in HLA-DPB1 cell surface and transcriptional expression levels
between the two rs9227534 variants are abrogated after IFN-
γ stimulation, and could not be observed in either mature or
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FIGURE 6 | Expression model and TCE Structural model for HLA-DPB1 mismatches in HSCT. (A) Genetic control of HLA-DP expression levels is mediated by the
biallelic SNP rs9277534, with a high expression G- and a low expression A-variant (5). Three distinct TCE groups with decreasing immunogenicity are determined by
structural amino acid variability in the peptide binding domain (PBD) encoded by exon 2 in the HLA-DPB1 coding region (9, 15). (B) For Expression matching, only
truly single HLA-DPB1 allele mismatches in GvH direction are considered, leading to a number of combinations that cannot be classified (in gray). For the others,
(Continued)
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FIGURE 6 | favorable (low risk, in green) and unfavorable (high risk, in pink) pairs are those where the mismatched allele in the patient carries the low expression
rs9277534-A or the high expression rs9277534-G variant, respectively (8). For TCE Structural matching, favorable (permissive, in green) pairs are those in which
patient and donor share at least one HLA-DPB1 allele from the TCE group with the highest immunogenicity; the others are predicted to be unfavorable
(non-permissive, in pink) (9, 11). (C) Percentage of favorable and unfavorable HLA-DPB1 mismatches according to the Expression model or the TCE Structural model
in 379 donor-recipient pairs from the University Hospital Essen. Pies indicate the percentage of favorable (low risk or permissive, in green) or unfavorable (high risk or
non-permissive, in pink) combinations according to the two models, or of pairs that cannot be classified by the Expression model (not applicable, gray). Classification
by the two models has a 36.7% concordance (filled boxes in the cross-tabulation), and 63.3% discordances (striped boxes in the cross-tabulation), either due to
differential risk assignment (background green or pink) or to non-applicability of the Expression model (background gray).
FIGURE 7 | HLA-DPB1 transcriptional expression in BLCL or transduced HeLa-II in relation with rs9277534 and TCE groups. (A) The most frequent HLA-DPB1
alleles from TCE group 1 and 3 are linked with rs9277534-G and -A, respectively (16). Notable exceptions are HLA-DPB1*17:01 (TCE 1), HLA-DPB1*01:01 and
HLA-DPB1*05:01 (both TCE 3), in which this association is inverted. Endogenous HLA-DPB1 expression is predicted to be genetically regulated by the
rs9277534-G/A SNP in the 3′UTR, while this regulation is abrogated in cells transfected with the HLA-DPB1 coding region under a retroviral promoter in the absence
of the 3′UTR. (B) Transcriptional expression of HLA-DPB1 in BLCL or transduced HeLa-II. HLA-DPB1 mRNA was quantified by RT-qPCR relative to GAPDH in BLCL
homozygous for alleles from TCE 1 (rs9277534-G) or TCE 3 (rs9277534-A) (Table 1), or in HeLa-II after retroviral vector transduction with the same alleles. Shown are
the mean results and SD from 3 independent experiments. Statistical comparisons were performed by the two-tailed unpaired t-test (***p < 0.001).
immature DC. Although a simplistic model, IFN-γ stimulation
can be seen as a simulation of an inflammatory environment
that can be induced by different triggers such as the conditioning
regimen or infection after HSCT, and has been described as
one of the most relevant cytokines mediating toxic effects of
GvHD after HSCT (32). In addition, DC are crucial APCs for
inducing alloresponses particularly from naïve T cells (33, 34).
The observation that genetic control of HLA-DP expression
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FIGURE 8 | T-cell allorecognition of HLA-DPB1 from different TCE groups expressed by HeLa-II. PBMC from HLA-DPB1 TCE 1-negative responders carrying at least
one HLA-DPB1 TCE 3 were stimulated with irradiated HeLa-II transduced with allogeneic HLA-DPB1 TCE 1 or TCE 3 for 14 d, as described in Materials and
Methods. For HLA-DPB1 typing of responders see Table 2. Cultures were re-stimulated for 24 h with HeLa-II expressing the original allogeneic HLA-DPB1, or with
autologous HLA-DPB1, and the percentage of CD4+ T cells expressing the CD137 activation marker was assayed by flow cytometry. (A) Gating strategy and
representative FACS plots for re-stimulation with autologous HLA-DPB1 or with allogeneic HLA-DPB1 from TCE 1 or TCE 3. Note the higher percentage of CD137+
CD4+ T cells in response to TCE 1 compared to TCE 3. (B) Results of CD137 assays in response to TCE 1, TCE 3 or HLA-DPB1*17:01, *01:01 or *05:01 for a total
of 178 independent co-cultures. Statistical comparisons were performed by the two-tailed unpaired t-test (*p < 0.05; **p < 0.01; ****p < 0.0001).
by the rs9227534 variation appears to be dampened under
these conditions challenges its relevance in the clinical setting.
However, it has to be noted that ours are in vitromodels that may
not fully reflect the in vivo situation. Moreover and importantly,
monocytes and B cells in a non-inflammatory context can have an
important role in triggering alloimmunity, in particular from the
memory T-cell repertoire, which is involved in direct recognition
of major histocompatibility antigen mismatches (35, 36).
We are also the first to attempt a mechanistic understanding
of the observed genetic control of HLA-DPB1 expression in
BLCL. The data we obtained by 3′UTR mapping and analysis
in luciferase assays in BLCL argue against a direct regulatory
role of rs9277534 or of any other linked SNP in the 3′UTR.
A limitation here is again that this in vitro assay might not
adequately reflect the in vivo situation, which is likely to be
considerably more complex, leaving us with the possibility that
the interplay of different factors might still lead to a direct
SNP regulation of expression. We also did not obtain evidence
for alternative splicing associated with the linked intron 2 STR
(37). An alternative role of this STR might be transcriptional
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repression rather than alternative splicing, a possibility we were
unable to test due to the unavailability of an appropriate in vitro
model. In line with observations made by others for HLA-A (2),
we show that also the HLA-DPB1 3′UTR contains two alternative
PAS giving rise to a short and a longmRNA transcript. In contrast
to their observations on HLA-A, however, the long HLA-DPB1
transcript was expressed at markedly lower levels compared to
the short one. This further argues against a dominant direct role
of the rs9277534 SNP in HLA-DPB1 expression, since this SNP
is contained in the long but not in the majorly abundant short
mRNA transcript. Nevertheless, a role of the SNP in binding
factors involved in determining the stability of the long mRNA,
such as described for HLA-A, cannot be ruled out.
Regarding risk prediction by the Expression model and the
TCE structural model in HSCT, we show a relatively limited
degree of 36.7% concordance in our exemplary cohort, which
however was due in the majority of cases to non-applicability
of the Expression model. It should be noted that the Expression
model requires the presence of a single HLA-DPB1 mismatch
in GvH direction, thereby precluding its application in almost
half of the pairs under analysis. In 203 pairs where risk
prediction could be performed by both models, concordance
was 68.5%, with discordances evenly distributed between high
risk/permissive and low risk/non-permissive pairs. These data
might be useful for clinicians intending to apply either model in
unrelated donor searches. The clinical cohort was too small to
make any meaningful comparative outcome analysis, and future
studies in large well-powered studies are clearly warranted to
understand the comparative clinical validity of the two models.
From the experimental side, we confirm and extend
our previous observations that non-permissive HLA-DPB1
TCE group mismatches elicit significantly stronger T-cell
alloresponses compared to permissive mismatches in vitro (31,
38). The observation that this holds true also independently from
HLA-DPB1 expression levels is in line with our unpublished
evidence that permissiveness of TCE group mismatches is
dependent on the HLA-DP peptidome (in preparation). This
finding is of practical relevance for the 3 HLA-DPB1 alleles
with inverted haplotype association studied here, i.e., HLA-
DPB1∗17:01, ∗01:01, and ∗05:01, which together have a 8.61%
frequency in Europeans (39). While our data confirm the
assignment to TCE group 1 of HLA-DPB1∗17:01, they suggest
that HLA-DPB1∗01:01 and ∗05:01 belong to a yet distinct
functional TCE group. Interestingly, it has recently been
suggested that HLA-DPB1 alleles could be divided into two
supertypes having HLA-DP2 and DP5 as respective prototypes
(40). This division was based on the allele frequency profile of
the Japanese population, and was correlated with the incidence
of acute GvHD after unrelated HSCT. The HLA-DP2 and DP5
supertypes closely resemble our TCE group 3 and TCE group 1/2,
respectively, with the main exception being HLA-DP5. The data
from the present study corroborate the functional distinctness of
HLA-DP5, despite its FD score of 2.97 which is clearly compatible
with its assignment to TCE group 3 (FD score >2.00) (15). Based
on these considerations, and on our unpublished findings on
the role of peptides in determining HLA-DP permissiveness, we
suggest that TCE group 3, which was coined to accommodate
all alleles not included in TCE groups 1 and 2, might be
more heterogeneous than expected. In line with this, we have
previously suggested that HLA-DP2 might constitute a separate
TCE4 group, and shown clinical associations equal to or in some
cohorts superior to the 3-group TCE algorithm with clinical
outcome (10, 11). Further studies are clearly needed to verify this
important point.
In conclusion, the data from the present study suggest that
genetic control of HLA-DPB1 expression is cell-type dependent
and dampened by inflammatory conditions. While we failed to
identify a mechanism for the observed association of HLA-DPB1
expression levels with rs9277534 SNP variation in certain cell
types under steady state conditions, our data argue against a
direct role of this SNP and in favor of indirect mechanisms
mediated by linked polymorphisms. The data on clinical risk
prediction by the Expression model and the TCE structural
model, as well as those on significant modulation of in
vitro T cell alloreactivity by HLA-DPB1 TCE groups in the
presence of similar transcriptional expression levels, suggest that
the two models are partially overlapping yet largely distinct.
These findings are of both biological and potentially clinical
relevance for investigators interested in unrelated stem cell donor
selection.
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